William Marsh Rice University acquired a new stake in shares of Veracyte, Inc. (NASDAQ:VCYT) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 13,822 shares of the biotechnology company’s stock, valued at approximately $127,000. Veracyte makes up 0.1% of William Marsh Rice University’s holdings, making the stock its 4th largest position.
Several other hedge funds also recently added to or reduced their stakes in the stock. Cannell Capital LLC bought a new stake in Veracyte during the third quarter valued at $2,897,000. State Street Corp raised its stake in shares of Veracyte by 13.1% in the fourth quarter. State Street Corp now owns 167,368 shares of the biotechnology company’s stock worth $1,297,000 after buying an additional 19,361 shares during the period. Oxford Asset Management acquired a new stake in shares of Veracyte during the fourth quarter worth approximately $764,000. Stonepine Capital Management LLC acquired a new stake in shares of Veracyte during the fourth quarter worth approximately $7,512,000. Finally, Trexquant Investment LP purchased a new stake in Veracyte during the fourth quarter valued at about $161,000. Institutional investors own 63.10% of the company’s stock.
Veracyte, Inc. (NASDAQ VCYT) traded up 2.48% on Monday, hitting $7.86. 68,126 shares of the company traded hands. Veracyte, Inc. has a 1-year low of $4.82 and a 1-year high of $9.71. The firm’s market capitalization is $266.22 million. The firm’s 50 day moving average price is $8.06 and its 200 day moving average price is $8.07.
Veracyte (NASDAQ:VCYT) last issued its quarterly earnings results on Wednesday, May 3rd. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.24). The company had revenue of $16.43 million for the quarter, compared to the consensus estimate of $18.09 million. Veracyte had a negative return on equity of 66.79% and a negative net margin of 43.40%. Equities research analysts predict that Veracyte, Inc. will post ($0.92) EPS for the current fiscal year.
Several analysts have recently issued reports on the stock. Zacks Investment Research lowered shares of Veracyte from a “buy” rating to a “hold” rating in a research note on Tuesday, March 7th. Cantor Fitzgerald set a $13.00 price target on shares of Veracyte and gave the stock a “buy” rating in a report on Thursday, May 18th. Finally, BTIG Research reissued a “buy” rating and issued a $12.00 price target on shares of Veracyte in a report on Friday, March 10th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $11.20.
In other news, Chairman Bonnie H. Anderson sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 21st. The stock was sold at an average price of $9.09, for a total value of $45,450.00. Following the transaction, the chairman now owns 15,000 shares in the company, valued at $136,350. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 13.40% of the company’s stock.
Veracyte Company Profile
Veracyte, Inc is a genomic diagnostics company. The Company uses genomic technology to resolve diagnostic ambiguity. It targets diseases in which patients undergo invasive diagnostic procedures. Its products combine genomic technology, clinical science and machine learning. The Company commercializes over three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis.
Receive News & Ratings for Veracyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte Inc. and related companies with our FREE daily email newsletter.